One LuitpOLd drive | pO BOx 9001 | ShirLey, ny 11967 | 800-645-1706 | www.americanregent.cOm

Betamethasone Sodium Phosphate & Betamethasone Acetate injectable Suspension, uSp**Betamethasone 6 mg/mL as 3 mg/mL Betamethasone Sodium Phosphate and 3 mg/mL Betamethasone Acetate.

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Important Safety Information: As with any potent corticosteroid, adverse events have been associated with Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, including fluid and electrolyte disturbances, as well as adverse reactions involving the following systems: allergic reactions, cardiovascular, dermatologic, endocrine, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, and ophthalmic. Corticosteroids may also affect immune response. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP should not be administered intravenously or used in systemic fungal infections. Vaccination administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop fever or other signs of infections. Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles and to seek medical advice without delay if exposed.

Depo-Medrol® is a registered trademark of Pfizer, Inc. Kenalog® is a registered trademark of Apothecon, Inc.

† Adapted from Garber, Targoff C, Paulus HE: Glucocorticoid preparations. In Paulus HE, Furst DE, Droomgoole SH (eds): Drugs for Rheumatic Diseases. New York, Churchill Livingstone, 1987, p 446.

Full prescribing information enclosed.

BB021, Iss. 5/2011

dOeS yOurpatient need tO waitdayS FOrreLieF?Betamethasone Sodium Phosphate & Betamethasone Acetate injectable Suspension, uSp

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Free ester glucocorticoid preparations†

• High Anti-Inflammatory Potency • Minimal Sodium-Retaining Potency• Low Equivalent Dose • Long Plasma & Biological Half-Life

(comparison of anti-inflammatory potency only; no suggestion of superior efficacy or safety intended)

Benefits of a dual agent corticosteroid for painful inflammatory conditions1

Within 1 – 2 hours after injection, the fast acting BSP begins to reduce pain and inflammation, while the less soluble BA rests in the intra-articular space

Knee joint with inflamed tissues immediately after injection

Days after injection, as the fast acting BSP is converted into FEB, the long lasting BA solubilizes, and continues to reduce pain and inflammation

A week after injection, both the BSP and BA have converted into biologically active FEB for continuing pharmacological activity

Betamethasone Sodium Phosphate (BSP)Betamethasone Acetate (BA)Free Ester Betamethasone (FEB)

LEGEND

Betamethasone Sodium Phosphate & Betamethasone Acetate injectable Suspension, uSp

2

1

3

4 Your patients don’t need to wait days for relief! • Fast acting - Begins to reduce inflammation in 1-2 hours • Long lasting - Provides sustained relief

Anti-Inflammatory Equivalent Dose Sodium-Retaining Plasma Half-life Biologic Half-life Potency (mg) Potency (min) (hr)

Cortisone 0.8 25 2+ 30 8 – 12

Hydrocortisone 1 20 2+ 90 8 – 12 Prednisone 4 5 1+ 60 12 – 36 Prednisolone 4 5 1+ 200 12 – 36 Methylprednisolone 5 4 0 180 12 – 36 Triamcinolone 5 4 0 300 12 – 36 Dexamethasone 20 – 30 0.75 0 100 – 300 36 – 54 Betamethasone 20 – 30 0.75 0 100 – 300 36 – 54

Betamethasone Sodium Phosphate &

Betamethasone Acetate Injectable Suspension, USP

Kenalog® (Triamcinolone

Acetonide) Injectable Suspension, USP

Depo-Medrol® (Methylprednisolone Acetate Injectable Suspension, USP)

Dexamethasone Sodium Phosphate

Injection, USP

3 – – –

Betamethasone has one of the highest anti-inflammatory potencies

Fast Acting and Long Lasting Formulation in 1 Product

1 Duration of relief varies among labeled indications.

One LuitpOLd drive | pO BOx 9001 | ShirLey, ny 11967 | 800-645-1706 | www.americanregent.cOm

Betamethasone Sodium Phosphate & Betamethasone Acetate injectable Suspension, uSp**Betamethasone 6 mg/mL as 3 mg/mL Betamethasone Sodium Phosphate and 3 mg/mL Betamethasone Acetate.

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Important Safety Information: As with any potent corticosteroid, adverse events have been associated with Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, including fluid and electrolyte disturbances, as well as adverse reactions involving the following systems: allergic reactions, cardiovascular, dermatologic, endocrine, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, and ophthalmic. Corticosteroids may also affect immune response. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP should not be administered intravenously or used in systemic fungal infections. Vaccination administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop fever or other signs of infections. Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles and to seek medical advice without delay if exposed.

Depo-Medrol® is a registered trademark of Pfizer, Inc. Kenalog® is a registered trademark of Apothecon, Inc.

† Adapted from Garber, Targoff C, Paulus HE: Glucocorticoid preparations. In Paulus HE, Furst DE, Droomgoole SH (eds): Drugs for Rheumatic Diseases. New York, Churchill Livingstone, 1987, p 446.

Full prescribing information enclosed.

BB021, Iss. 5/2011

dOeS yOurpatient need tO waitdayS FOrreLieF?Betamethasone Sodium Phosphate & Betamethasone Acetate injectable Suspension, uSp

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.